Xencor Inc. Annual Report Snapshot: 2023 Performance and Future Outlook

Curious about Xencor Inc.'s 2023 performance? This summary cuts through the technical language of their annual report (Form 10-K) to deliver the essential facts. We'll explore their business, financial health, and future prospects, helping you understand if Xencor aligns with your investment strategy.

What Xencor Does: Pioneering Antibody and Protein Therapeutics

Xencor Inc. is a clinical-stage biotechnology company that discovers and develops innovative antibody and protein treatments. Their core strength lies in their proprietary XmAb® technology platform. This platform allows Xencor to engineer antibodies and other proteins to improve their therapeutic properties. For instance, they can enhance a treatment's ability to bind to targets, extend its duration in the body, or create "bispecific" antibodies that can engage two different targets simultaneously. This advanced technology aims to create more effective and safer treatments for serious diseases, including cancer and autoimmune disorders.

Xencor's business model primarily involves advancing its own drug candidates through early clinical development. The company then partners with larger pharmaceutical companies for late-stage development, regulatory approval, and commercialization. Xencor generates revenue through several channels:

• License Agreements: Granting partners rights to use their XmAb technology or specific drug candidates.
• Milestone Payments: Receiving payments when partnered programs achieve specific development, regulatory, or commercial milestones.
• Royalties: Earning a percentage of sales on approved products developed using their technology.
• Research & Development Collaborations: Securing funding from partners for joint R&D efforts.

Xencor's pipeline features several promising drug candidates, each leveraging their XmAb technology to address specific medical needs:

• Plamotamab (XmAb13676): A bispecific antibody targeting CD20 and CD3, currently in Phase 2 clinical trials for non-Hodgkin lymphoma. This is an Xencor-owned program.
• XmAb808: A bispecific antibody targeting B7-H3 and CD3, in Phase 1 clinical trials for advanced solid tumors. This is also an Xencor-owned program.
• XmAb541: An IL15/IL15Rα-Fc fusion protein, in Phase 1 clinical trials for solid tumors.
• XmAb819: An anti-ENPP3 antibody-drug conjugate (ADC), in Phase 1 clinical trials for renal cell carcinoma.
• XmAb657: A bispecific antibody targeting CD38 and CD3, in preclinical development for hematologic malignancies.
• Other early-stage programs like XmAb942 and XmAb412 are in preclinical development, targeting various cancers and autoimmune diseases.

Strategic Partnerships: Driving Development and Expansion

Xencor's extensive network of partnerships is fundamental to its strategy. These collaborations provide crucial funding, development expertise, and broader market reach. Such agreements often include significant upfront payments, research funding, and potential milestone and royalty payments. Key partners include:

• Alexion Pharmaceuticals Inc.: Collaborating on XmAb541 (IL15/IL15Rα-Fc fusion protein).
• Amgen Inc.: Partnering on XmAb5871 (targeting CD19 for autoimmune diseases).
• Gilead Sciences: Collaborating on multiple bispecific antibody programs.
• Janssen Biotech Inc.: Partnering on XmAb14045 (CD123 x CD3 bispecific antibody).
• Incyte Corporation: Collaborating on multiple bispecific antibody programs.
• Novartis: Partnering on certain XmAb-engineered antibodies.
• Zenas BioPharma Limited: Collaborating on the development and commercialization of obexelimab (XmAb5871) in specific territories.
• Other partners like MorphoSys, Novo Nordisk HealthCare AG, Omeros, Shanghai Mabgeek Biotech Co. Ltd., Vega Therapeutics Inc., and Vir Biotechnology Inc. contribute to a diverse portfolio of partnered programs across various therapeutic areas.

Financial Performance: 2023 Highlights (Management Discussion & Analysis)

For the fiscal year ended December 31, 2023, Xencor reported the following key financial highlights. Management emphasized that the increase in total revenue demonstrates the value of its XmAb platform and successful partnership strategy. The increased net loss and R&D expenses, conversely, reflect strategic investments in advancing Xencor's own clinical pipeline.

• Total Revenue: Approximately $250 million, primarily from collaboration and license revenue from existing and new partnerships, including upfront payments and milestone achievements. This marks a significant increase from $180 million in the prior year, reflecting successful deal-making and pipeline progress.
• Net Loss: A net loss of approximately $120 million, or ($2.05) per share. This is common for a clinical-stage biotech company heavily investing in research and development. The loss widened slightly from $100 million in 2022 due to increased R&D expenses.
• Research and Development (R&D) Expenses: Increased to approximately $280 million (from $220 million in 2022), reflecting Xencor's commitment to advancing its own pipeline and supporting partnered programs. This remains their largest expense category.
• General and Administrative (G&A) Expenses: Approximately $60 million, supporting corporate operations.
• Cash, Cash Equivalents, and Marketable Securities: Xencor maintained a strong cash position, ending the year with approximately $550 million. This includes cash, money market funds, investments in corporate debt, and U.S. Treasury bonds. This robust cash balance is crucial for funding ongoing R&D and operations, providing an estimated cash runway into late 2026. The company had no significant long-term debt as of December 31, 2023, relying primarily on equity financing and collaboration revenues to fund operations.
• Investments: Xencor also holds strategic equity investments in other biotech companies, such as INmune Bio, Viridian Therapeutics, and Zenas BioPharma, valued at approximately $75 million.

Management highlighted that the company's robust cash position provides critical financial flexibility and is considered sufficient to support its operational plans and pipeline development for the foreseeable future.

Key Developments and 2024 Outlook

In 2023, Xencor achieved several significant milestones:

• Reported positive clinical trial results for Plamotamab in non-Hodgkin lymphoma, supporting its continued advancement.
• Initiated new clinical trials for XmAb808 in solid tumors.
• Expanded existing partnerships and formed new collaborations, bringing in additional funding that did not require issuing new shares.

Looking ahead to 2024, Xencor's strategic priorities include:

• Advancing Plamotamab through its ongoing Phase 2 trial and exploring paths to regulatory approval.
• Generating initial clinical data for XmAb808 and other early-stage, Xencor-owned programs.
• Continuing to leverage their XmAb platform to discover new drug candidates and expand their pipeline.
• Exploring new partnership opportunities to maximize the value of their technology and pipeline assets.
• Maintaining a disciplined approach to capital allocation to extend their cash runway.

Understanding the Risks

Investing in a clinical-stage biotechnology company like Xencor involves inherent risks that investors should consider:

• Clinical Trial Success: Most drug candidates fail during clinical development. There is no guarantee that Xencor's or its partners' programs will achieve positive results or regulatory approval.
• Regulatory Approval: Even with positive clinical data, obtaining regulatory approval from agencies like the FDA is a complex and uncertain process.
• Competition: The biotechnology industry is highly competitive. Xencor's drug candidates may face competition from existing treatments or other novel therapies.
• Intellectual Property: Xencor's success depends on its ability to protect its XmAb technology and drug candidates through patents.
• Dependence on Partners: A significant portion of Xencor's revenue and pipeline advancement relies on the success and commitment of its collaboration partners.
• Need for Future Funding: While Xencor has a strong cash position, the company may require future funding to continue its extensive R&D efforts, which could lead to dilution for existing shareholders.

Competitive Position

Xencor operates in the highly competitive biopharmaceutical industry, an environment characterized by rapid technological change and intense competition from pharmaceutical, biotechnology, and specialty pharmaceutical companies. Xencor's primary competitive advantage stems from its proprietary XmAb® technology platform, which enables the engineering of antibodies and proteins with enhanced therapeutic properties. This platform allows Xencor to develop differentiated drug candidates and attract strategic partners.

However, many of Xencor's competitors, including its partners, possess significantly greater financial resources, larger research and development teams, and more extensive marketing and manufacturing capabilities. Xencor's ability to compete effectively depends on its capacity to:

• Successfully develop and obtain regulatory approval for its drug candidates.
• Protect its intellectual property.
• Attract and retain skilled personnel.
• Form and maintain strategic collaborations.
• Manufacture products cost-effectively.

The success of Xencor's drug candidates will also depend on their efficacy, safety, and cost-effectiveness compared to existing and future treatments for the same indications.

Xencor represents a high-risk, high-reward investment opportunity, driven by its innovative technology platform, a robust pipeline of drug candidates, strategic partnerships, and a healthy cash balance.